Literature DB >> 17485604

Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia.

Dean F Salisbury1, Noriomi Kuroki, Kiyoto Kasai, Martha E Shenton, Robert W McCarley.   

Abstract

CONTEXT: Progressive brain abnormalities in schizophrenia remain controversial. Evidence of interrelated progressive functional impairment would buttress the case for structural progression. Mismatch negativity (MMN) is reduced in chronic but not first-hospitalized schizophrenia and may index progressive structural changes.
OBJECTIVE: To determine whether MMN shows associations with underlying auditory cortex gray matter at first hospitalization and progressive reduction longitudinally.
DESIGN: Cross-sectional (first hospitalization) and longitudinal (1.5-year follow-up).
SETTING: A private psychiatric hospital. PARTICIPANTS: Protocol entrance: MMN and magnetic resonance imaging at first hospitalization in 20 subjects with schizophrenia, 21 subjects with bipolar disorder with psychosis, and 32 control subjects. Longitudinal electrophysiologic testing: MMN in 16 subjects with schizophrenia, 17 subjects with bipolar disorder, and 20 control subjects. Longitudinal electrophysiologic testing and magnetic resonance imaging: MMN and magnetic resonance imaging in 11 subjects with schizophrenia, 13 subjects with bipolar disorder, and 13 control subjects. At each time point, reported samples were group matched for age, handedness, and parental socioeconomic status.
INTERVENTIONS: Electrophysiologic testing and high-resolution structural magnetic resonance imaging. MAIN OUTCOME MEASURES: Mismatch negativity amplitude and Heschl gyrus and planum temporale gray matter volumes.
RESULTS: Initially, groups did not differ in MMN amplitude. Subjects with schizophrenia showed associations between MMN and Heschl gyrus (r=-0.52; P=.02) not present in the other groups. At longitudinal MMN testing, schizophrenia showed MMN reduction (P=.004). Only schizophrenia evinced longitudinal left hemisphere Heschl gyrus reduction (P=.003), highly correlated with MMN reduction (r=0.6; P=.04).
CONCLUSIONS: At first hospitalization for schizophrenia, MMN indexed left hemisphere Heschl gyrus gray matter volume, consistent with variable progression of pre-hospitalization cortical reduction. Longitudinally, the interrelated progressive reduction of functional and structural measures suggests progressive pathologic processes early in schizophrenia. An active process of progressive cortical reduction presents a potential therapeutic target. Mismatch negativity may be a simple, sensitive, and inexpensive index not only of this progressive pathologic process but also of successful intervention.

Entities:  

Mesh:

Year:  2007        PMID: 17485604      PMCID: PMC2903200          DOI: 10.1001/archpsyc.64.5.521

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  54 in total

1.  Progressive brain volume loss during adolescence in childhood-onset schizophrenia.

Authors:  Alexandra L Sporn; Deanna K Greenstein; Nitin Gogtay; Neal O Jeffries; Marge Lenane; Peter Gochman; Liv S Clasen; Jonathan Blumenthal; Jay N Giedd; Judith L Rapoport
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Authors:  Wiepke Cahn; Hilleke E Hulshoff Pol; Elleke B T E Lems; Neeltje E M van Haren; Hugo G Schnack; Jeroen A van der Linden; Patricia F Schothorst; Herman van Engeland; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2002-11

4.  Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia.

Authors:  Robert A Sweet; Joseph N Pierri; Sungyoung Auh; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2002-12-03       Impact factor: 7.853

5.  Associated deficits in mismatch negativity generation and tone matching in schizophrenia.

Authors:  D C Javitt; A Shelley; W Ritter
Journal:  Clin Neurophysiol       Date:  2000-10       Impact factor: 3.708

6.  Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study.

Authors:  D H Mathalon; E V Sullivan; K O Lim; A Pfefferbaum
Journal:  Arch Gen Psychiatry       Date:  2001-02

7.  Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia.

Authors:  D C Javitt; P Doneshka; S Grochowski; W Ritter
Journal:  Arch Gen Psychiatry       Date:  1995-07

8.  Mismatch negativity to auditory stimulus change recorded directly from the human temporal cortex.

Authors:  J D Kropotov; R Näätnen; A V Sevostianov; K Alho; K Reinikainen; O V Kropotova
Journal:  Psychophysiology       Date:  1995-07       Impact factor: 4.016

9.  Mismatch negativity in chronic schizophrenia and first-episode schizophrenia.

Authors:  Dean F Salisbury; Martha E Shenton; Carlye B Griggs; Aaron Bonner-Jackson; Robert W McCarley
Journal:  Arch Gen Psychiatry       Date:  2002-08

10.  Schizophrenia syndromes associated with changes in ventricle-to-brain ratios: a serial high-resolution three-dimensional magnetic resonance imaging study in first-episode schizophrenia patients using subvoxel registration and semiautomated quantification.

Authors:  B K Puri; N Saeed; A J Richardson; A Oatridge; J V Hajnal; G M Bydder
Journal:  Int J Clin Pract       Date:  2005-04       Impact factor: 2.503

View more
  137 in total

1.  Delayed preattentional functioning in early psychosis patients with cannabis use.

Authors:  Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2012-03-09       Impact factor: 4.530

2.  Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia.

Authors:  Caitlin E Moyer; Kristen M Delevich; Kenneth N Fish; Josephine K Asafu-Adjei; Allan R Sampson; Karl-Anton Dorph-Petersen; David A Lewis; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2012-05-23       Impact factor: 13.382

Review 3.  Psychiatric Illnesses as Oscillatory Connectomopathies.

Authors:  Sophia Vinogradov; Alexander Herman
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

Review 4.  Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Authors:  Daniel C Javitt
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

5.  Progressive brain changes in schizophrenia.

Authors:  Celso Arango; René Kahn
Journal:  Schizophr Bull       Date:  2008-01-22       Impact factor: 9.306

Review 6.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

7.  Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders.

Authors:  Gregory A Light; Risto Näätänen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-30       Impact factor: 11.205

8.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 9.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

Review 10.  Auditory cortex asymmetry, altered minicolumn spacing and absence of ageing effects in schizophrenia.

Authors:  Steven A Chance; Manuel F Casanova; Andy E Switala; Timothy J Crow
Journal:  Brain       Date:  2008-09-26       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.